Compare · AMPX vs TMO
AMPX vs TMO
Side-by-side comparison of Amprius Technologies Inc. (AMPX) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- AMPX operates in Miscellaneous, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $174.52B, about 65.4x AMPX ($2.67B).
- Over the past year, AMPX is up 498.9% and TMO is up 14.9% - AMPX leads by 484.0 points.
- TMO has been more active in the news (17 items in the past 4 weeks vs 15 for AMPX).
- TMO has more recent analyst coverage (25 ratings vs 9 for AMPX).
- Company
- Amprius Technologies Inc.
- Thermo Fisher Scientific Inc
- Price
- $19.23-2.34%
- $469.56-0.67%
- Market cap
- $2.67B
- $174.52B
- 1M return
- +16.81%
- -1.03%
- 1Y return
- +498.89%
- +14.92%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NYSE
- NYSE
- IPO
- 2022
- News (4w)
- 15
- 17
- Recent ratings
- 9
- 25
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest AMPX
- SEC Form 144 filed by Amprius Technologies Inc.
- Chief Executive Officer Stepien Thomas M sold $41,940 worth of shares (2,000 units at $20.97), gifted 67,298 shares and received a gift of 36,914 shares, decreasing direct ownership by 10% to 625,625 units (SEC Form 4)
- Amprius Sets June 2026 Events Schedule
- Director Sun Kang sold $6,121 worth of shares (356 units at $17.19), decreasing direct ownership by 0.03% to 1,280,498 units (SEC Form 4) (withholding obligation)
- SEC Form 144 filed by Amprius Technologies Inc.
- Chief Executive Officer Stepien Thomas M sold $75,222 worth of shares (4,375 units at $17.19), decreasing direct ownership by 0.63% to 694,923 units (SEC Form 4) (for withholding tax)
- Chief Technology Officer Stefan Constantin Ionel sold $55,157 worth of shares (3,208 units at $17.19), decreasing direct ownership by 0.40% to 801,310 units (SEC Form 4) (withholding tax)
- Director Dixon Donald R sold $320,252 worth of shares (17,895 units at $17.90) (SEC Form 4)
- Director Sun Kang sold $1,002,594 worth of shares (67,796 units at $14.79), decreasing direct ownership by 5% to 1,280,854 units (SEC Form 4) to satisfy tax liability
- SEC Form 144 filed by Amprius Technologies Inc.
Latest TMO
- Thermo Fisher downgraded by HSBC Securities with a new price target
- Wolfe Research resumed coverage on Thermo Fisher with a new price target
- SEC Form SD filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Weisler Dion J covered exercise/tax liability with 80 shares and was granted 499 shares, increasing direct ownership by 8% to 5,446 units (SEC Form 4)
- Director Sperling Scott M was granted 499 shares, increasing direct ownership by 0.72% to 69,479 units (SEC Form 4)
- Director Spar Debora L was granted 499 shares, increasing direct ownership by 24% to 2,610 units (SEC Form 4)
- Director Lynch Karen S was granted 499 shares, increasing direct ownership by 76% to 1,159 units (SEC Form 4)
- Director Keith R. Alexandra was granted 499 shares, increasing direct ownership by 24% to 2,602 units (SEC Form 4)